Next Article in Journal
The assessment of clinical evaluation and treatment results of high-energy blunt polytrauma patients
Previous Article in Journal
Ischemic heart disease: structural changes of the atria in preinfarction and postinfarction stages
Medicina is published by MDPI from Volume 54 Issue 1 (2018). Articles in this Issue were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence. Articles are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Lithuanian Medical Association, Lithuanian University of Health Sciences, and Vilnius University.
Open AccessArticle

Secondary prevention of ischemic heart disease: pharmacological treatment after myocardial infarction according to follow-up protocol

1
Institute of Cardiology
2
Clinic of Cardiology
3
Department of Theoretical and Clinical Pharmacology, Kaunas University of Medicine, Lithuania
*
Author to whom correspondence should be addressed.
Medicina 2007, 43(2), 131; https://doi.org/10.3390/medicina43020016
Received: 20 October 2006 / Accepted: 1 February 2007 / Published: 6 February 2007
The aim of this work was to assess the quality of pharmacological treatment in patients within one year after acute myocardial infarction.
Material and methods
. We performed a prospective survey of 985 consecutive patients with acute myocardial infarction who were treated in the Clinic of Cardiology of Kaunas University of Medicine Hospital in 2004. About half of patients were hospitalized from different regions of Lithuania. According to the follow-up protocol, an information on 514 patients and their used treatment within 13.8±3.2 months after myocardial infarction were collected by letter with questionnaire.
Results
. Beta-adrenoblockers, angiotensin-converting enzyme inhibitors, and antithrombotic drugs were the most drug used (76%, 74%, and 76%, respectively) in patients following myocardial infarction. Most of the patients used a three-drug combination (36.8%), more rarely – two-drug (24.1%) or four-drug complex (19.8%). One drug was used only in 12.1% of cases; 7.2% of patients did not use any cardiac drugs. Betaadrenoblocker with angiotensin-converting enzyme inhibitor was the most common (40.3%) used drug combination in patients on two drug complex. The combination of beta-adrenoblocker, angiotensin-converting enzyme inhibitor, and antithrombotics was more frequently used in patients on three drug complex. The combination of two or three cardiac drugs with statin was used in several cases (1.6–10.3%).
Conclusions
. These findings underscore that the use of beta-adrenoblockers, angiotensin-converting enzyme inhibitors, and antithrombotics was high (about 75%) in patients during the first year after myocardial infarction, and the combination of these three drugs was used more commonly. The discordance between existing guidelines for statin use after myocardial infarction and current practice was determined in patients following myocardial infarction.
Keywords: myocardial infarction; secondary prevention of ischemic heart disease; pharmacological treatment myocardial infarction; secondary prevention of ischemic heart disease; pharmacological treatment
MDPI and ACS Style

Milvidaitė, I.; Lukšienė, D.; Šlapikienė, B.; Babarskienė, M.R.; Liukaitis, V.; Mačiulaitis, R.; Kaduševičius, E.; Pilvinienė, R. Secondary prevention of ischemic heart disease: pharmacological treatment after myocardial infarction according to follow-up protocol. Medicina 2007, 43, 131.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop